Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. FDA Says Global Drug Safety On Importers’ Shoulders

This article was originally published in PharmAsia News

Executive Summary

U.S. FDA is grappling with the challenges of import safety as the number of foreign-sourced drugs entering the country exceeds FDA's inspection capabilities, and the agency hopes two risk-based draft guidances will increase industry accountability and free up resources for high-risk inspections
Advertisement

Related Content

FDA May Require Drug Importers To Verify Product Quality
FDA Supply Chain Initiative And Foreign Inspection Increases Funded Under White House ’10 Budget
FDA Supply Chain Initiative And Foreign Inspection Increases Funded Under White House ’10 Budget
In Wake Of Heparin Deaths, FDA Set To Launch Pilot Project Aimed At Preventing Imports Of Adulterated Drugs
In Wake Of Heparin Deaths, FDA Set To Launch Pilot Project Aimed At Preventing Imports Of Adulterated Drugs
U.S. FDA Launches First Overseas Office in Beijing
Advertisement
UsernamePublicRestriction

Register

SC071022

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel